Date: 2017-02-24
Type of information: Restructuring
Compound:
Company: Daiichi Sankyo (Japan)
Therapeutic area:
Type agreement: restructuring
Action mechanism:
Disease:
Details:
- On February 24, 2017, Daiichi Sankyo announced organizational changes taking place from April 1,2017. In order to accelerate the advancement of the Daiichi Sankyo Cancer Enterprise and strengthen its product portfolio management, “Global Brand Strategy Division,” will be newly established with the “Global Specialty & Value Products Marketing” and “Intellectual Property” departments falling under it. “Business Development & Licensing Department” will be moved under the President’s direct report with the intent of integrating global business development organizations.
In order to strengthen its translational function between drug research and development, and to accelerate the development of personalized medicines, related functions will be gathered in the newly established, “Biomarker Department,” which falls under the Oncology Function.
“Translational Medicine & Clinical Pharmacology Department” will mainly specialize in the function of clinical pharmacology and be renamed, “Clinical Pharmacology Department.”
Along with the integration of the biologics and biomarker-related functions, the medicinal safety research and drug metabolism and pharmacokinetic research function, as well as research management functions, will be transferred to the current “Research Function,” and the “Research Technology Function” will be abolished.
A “Biologics Division” will be newly established with the integration of biologics-related functions, including modality research, industrial science research, investigational product manufacturing, and commercial production functions. Within “Biologics Division,” “Biologics Planning Department” will be formed and “Modality Research Laboratories” and “Cell Therapy Laboratories” from the R&D Division, as well as “Biologics Technology Research Laboratories” from the Pharmaceutical Technology Division, will be transferred to “Biologics Division.” Furthermore, “Cell Therapy Laboratories” will be renamed, “Cell Therapy Research Laboratories.”
- On February 10, 2017, Daiichi Sankyo announced that, as a result of ongoing efforts to review its global R&D structure to increase R&D productivity, the company has decided to further reorganize its R&D structure by closing its Japanese research subsidiary, Asubio Pharma by the end of March 2018. Asubio Pharma is located in Kobe and has approximately 150 employees. The company mainly focuses on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine, conducting research based on its position a drug discovery venture within Daiichi Sankyo Group. Under this reorganization, Daiichi Sankyo plans to transfer Asubio Pharma R&D functions and employees to other Daiichi Sankyo Group companies in Japan. Further details regarding the reorganization scheme will be announced in the future.
Financial terms:
Latest news:
Is general: Yes
